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Objectives. We sought to assess whether oxidation products of
nitric oxide (NO), nitrite (NO2
2) and nitrate (NO3
2), referred to
as NOx, are released by the heart of patients after acute myocar-
dial infarction (AMI) and whether NOx can be determined in
peripheral blood of these patients.
Background. Previously we reported that in experimental myo-
cardial infarction (rabbits) NOx is released mainly by inflamma-
tory cells (macrophages) in the myocardium 3 days after onset of
ischemia. NOx is formed in heart muscle from NO; NO originates
through the activity of the inducible form of nitric oxide synthase
(iNOS).
Methods. Eight patients with acute anterior MI and an equal
number of controls were studied. Coronary venous blood was
obtained by coronary sinus catheterization; NOx concentrations in
coronary sinus, in arterial and peripheral venous plasma were
measured. Left ventricular end-diastolic pressure was deter-
mined. Measurements were carried out 24, 48 and 72 h after onset
of symptoms. The type and location of coronary arterial lesions
were determined by coronary angiography. Plasma NO3
2 was
reduced to NO2
2 by nitrate reductase before determination of
NO2
2 concentration by chemiluminescence.
Results. The results provided evidence that in patients with
acute anterior MI, the myocardial production of nitrite and
nitrate (NOx) was increased, as well as the coronary arterial–
venous difference. Increased NOx production by the infarcted
heart accounted for the increase of NOx concentration in arterial
and the peripheral venous plasma. The peak elevation of NOx
occurred on days 2 and 3 after onset of the symptoms, suggesting
that NOx production was at least in part the result of production
of NO by inflammatory cells (macrophages) in the heart.
Conclusions. The appearance of oxidative products of NO
(NO2
2 and NO3
2) in peripheral blood of patients with acute MI
is the result of their increased release from infarcted heart during
the inflammatory phase of myocardial ischemia. Further studies
are needed to define the clinical value of these observations.
(J Am Coll Cardiol 1998;32:373–9
©1998 by the American College of Cardiology
Nitric oxide (NO) is a free radical with an unpaired electron; it
is an important physiologic messenger, produced by nitric
oxide synthases, which catalyze the reaction L-arginine to
citrulline and NO. There are two main categories of NO
synthase, the constitutive and the inducible forms. The consti-
tutive isoforms exists in neuronal and endothelial cells and is
calcium dependent (1,2). Calcium binds to calmodulin and the
calcium calmodulin complex activates the constitutive NO
synthase that releases NO, relaxing smooth muscle cells
through activation of guanylate cyclase and the production
cGMP (3). Therefore, the NO produced has a negative ino-
tropic effect on the heart and is instrumental in the autoregu-
lation of the coronary circulation (4,5).
In contrast, the inducible form of NO synthase (iNOS) is
mostly produced in macrophages activated by cytokines and
endotoxin (6). It eliminates intracellular pathogens, damaging
cells by inhibiting ATP production and oxidative phosphoryla-
tion and DNA synthesis (7). In infection, lipopolysaccharide
released from bacterial walls, stimulates production of iNOS
primarily in macrophages (8). The large amount of NO
produced causes extensive vasodilation and hypotension. The
iNOS is also activated in heart muscle under pathologic
conditions, such as in heart failure, dilated cardiomyopathy
and cardiac allograft rejection (9,10). It has been found that in
infarcted rabbit heart muscle after ligation of a coronary
artery, iNOS activity increases on the first postoperative day
and persists for at least 14 days, declining to control levels 3
weeks after the onset of ischemia. iNOS was also localized in
infiltrating macrophages of the human heart (11). Animals
with myocardial ischemia showed consistent elevation of
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plasma nitrite (NO2
2) and nitrate (NO3
2) concentration 3
days after onset of myocardial infarction (12). Several findings
suggest a causal relationship between NO production by the
heart and elevated plasma levels of NOx, such as a relationship
in time between NOx plasma concentration and NOx produc-
tion and between coronary arteriovenous difference of NOx
and myocardial iNOS activity.
It is the purpose of this study to demonstrate that after
occlusion of the anterior descending coronary artery in hu-
mans, NOx plasma levels are elevated and that this is caused by
increased NOx production in the infarcted human heart
muscle.
Methods
Patients and methods. All participants in the study were
informed of the procedure and gave written consent. The
protocol was approved by the local ethics committees and is in
line with the recommendations of the Declaration of Helsinki.
The study involved 16 patients, of these eight (6 men, 2
women), aged 48 to 80 years (mean 65.0 6 3.3 years) with no
evidence of acute myocardial infarction (AMI) served as
control (Table 1). These patients were undergoing coronary
arteriography using a Judkins catheter (6F) for evaluation of
nonspecific chest pain and had no angiographic evidence of
significant coronary artery stenosis (Table 1). All control
patients were studied after an overnight fast and received 5,000
units of intravenous heparin at the initiation of the study.
Antianginal and antihypertensive medications were discontin-
ued at least 48 hours before this study. Routine cardiac
catheterization was performed using a femoral approach and a
biplane cineangio system (Toshiba). After a Cordis infinity
micro pigtail catheter (6F) was inserted into the left ventricle,
left ventricular end-diastolic pressure was recorded. Left ven-
triculography was performed and left ventricular ejection
fraction was calculated (Table 1). A coronary sinus catheter
(5F; Baxter) was placed in the coronary sinus (CS) through the
left subclavian vein and the position was confirmed by injection
of the contrast medium (iopamilone) and by typical position on
fluoroscopy (13). Blood samples for analysis were drawn from
the CS, femoral artery and femoral or brachial vein (hence-
forth referred to as the peripheral vein) before performing
coronary angiography. A Cordis infinity Judkins type catheter
(6F) was used for diagnostic coronary angiography.
Patients with acute myocardial infarction (AMI) (6 men, 2
women), aged 46 to 81 years (mean 66.0 5 4.5 years) (Table 1)
displayed evidence of infarction as documented by the follow-
ing criteria: 1) chest pain lasting $30 min; 2) electrocardio-
graphic ST-segment elevation of $0.1 mV in at least two leads
in either anterior or lateral distribution; and 3) elevated
creatine kinase MB isoenzymes within 24 h after the onset of
Abbreviations and Acronyms
AMI 5 acute myocardial infarction
CPK 5 creatine kinase
CS 5 coronary sinus
iNOS 5 inducible form of nitric oxide synthase
LAD 5 left anterior descending coronary artery
NO 5 nitric oxide
NO2
2 5 nitrite
NO3
2 5 nitrate
NOx 5 sum of nitrite and nitrate
RPP 5 rate pressure product
Table 1. Patient Characteristics and Hemodynamic Variables (Control and AMI)
Age
(y) Sex Smoking Medication
HR
(beats/min)
Mean BP
(mm Hg)
LVEDP
(mm Hg)
LVEF
(%)
Peak
CPK
(IU/liter)
CPK-MB
(IU/liter)
Culprit
Vessel†
(Coronary
Segment) Angio‡
Control group
1 59 M 1 None 67 100 7 74 — — None 0
2 71 M 1 None 70 102 8 63 — — None 0
3 65 M 2 None 59 112 12 68 — — None 0
4 80 M 2 None 79 105 10 53 — — None 0
5 66 F 2 None 90 110 13 72 — — None 0
6 69 F 2 None 74 92 6 60 — — None 0
7 48 M 2 None 70 125 8 68 — — None 0
8 62 M 1 None 75 109 11 71 — — None 0
AMI group*
1 74 M 1 Ca 74 96 9 — 2,989 774 LAD (6) 2
2 48 M 1 ACE 65 110 19 36 391 43 LAD (6) 1
3 81 M 1 ACE, Diu 87 82 14 52 1,112 173 LAD (7) 1
4 65 M 1 ACE, Ca 64 103 14 37 3,514 476 LAD (6) 2
5 68 F 2 ACE, Ca, Diu 76 100 15 39 1,546 289 LAD (6) 1
6 75 M 2 ACE, Ca, Diu 82 90 5 43 2,543 263 LAD (8) 2
7 46 M 1 ACE, b 85 106 11 52 4,648 468 LAD (6) 1
8 71 F 2 ACE, Diu 78 97 19 38 3,219 317 LAD (7) 1
*All patients had anterior myocardial infarction. †Location of obstruction in left anterior descending artery according to American Heart Association classification.
‡Number of stenosed coronary arteries. CPK 5 creatine kinase; CPK-MB 5 MB isoenzyme of creatine kinase; Culprit vessel 5 left anterior descending coronary artery;
Ca 5 calcium antagonist; ACE 5 angiotensin-converting enzyme inhibitor; Diu 5 diuretic (furosamide); b 5 beta-blocker; Angio 5 coronary angiography.
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symptoms. Excluded were patients with electrocardiographic
or historic evidence of previous myocardial infarction, coro-
nary artery bypass surgery or percutaneous transluminal coro-
nary angioplasty.
Tissue plasminogen activator or urokinase were not admin-
istered. Therapy included heparin and morphine when indi-
cated. In most cases patients with AMI had sublingual nitrate
once in the emergency room or catheterization laboratory
before or after coronary angioplasty. Blood was drawn for
determination of NOx .12 h after coronary angioplasty and
the administration of nitroglycerine. Patients with AMI were
subjected to cardiac catheterization within 6 h after onset of
symptoms. Coronary angiography and angioplasty were per-
formed using a standard femoral approach. All patients under-
went direct coronary angioplasty (mean time from onset of
chest pain to first inflation was 3.9 6 0.6 h). The culprit artery
was identified by coronary angiogram (Table 1). A significant
coronary artery stenosis was defined as .75% luminal narrow-
ing by visual estimate after intracoronary nitroglycerin (100 to
200 mg). The culprit arteries were revascularized using Scimed
Bandit coronary angioplasty dilation catheter (2.5 to 3.5 mm by
20 mm, Boston Scientific) to Thrombolysis in Myocardial
Infaction flow grade 3 until residual stenosis was ,50% (14).
Electrocardiographic ST-segment elevation decreased to nor-
mal levels in one patient (No. 2) after coronary angioplasty
(Table 1). The remaining patients displayed continuous ST-
segment elevation after coronary angioplasty. Sustained ven-
tricular tachycardia, ventricular fibrillation or atrial fibrillation/
flutter were not observed.
During hospitalization no patient had cardiogenic shock,
reinfarction or infection. At time of discharge coronary angiog-
raphy revealed that all culprit arteries had remained patent.
Measurement of plasma NO2
2 and NO3
2. Blood was
drawn in heparinized tubes for NO2
2 and NO3
2 determina-
tion, and immediately centrifuged at 1,200 g for 10 min for
removal of the formed elements by plasma separation. The
plasma samples were ultrafiltered using a micropartitioning
device at 4,000 g for 1 h (Centrifree Micropartition System) to
remove residual proteins. The deproteinized plasma samples
were frozen at 220°C until analysis by chemiluminescence
(15).
Analysis of NO2
2 1 NO3
2 required reduction of NO3
2 to
NO2
2 with aspergillus nitrate reductase (Sigma Chemical). All
samples were run in duplicate. Nitrate reductase 50 ml (0.2 U),
FAD 5 ml (5 mmol/liter), NADPH 5 ml (6 mmol/liter) and
phosphate buffer (1.2 mmol/liter) were added to 50 ml of
deproteinized plasma to yield a final volume of 150 ml and
subsequently incubated at 36°C for 1 h to allow for sufficient
conversion of NO3
2 to NO2
2. After incubation, 50 ml of the
sample were injected into the reaction vessel. The NO3
2
content of the sample was calculated by subtracting the
amount of NO2
2 in untreated samples from the amount of
NO2
2 in the reduced samples (12). The sample containing
nitrate reductase contains basal NO2
2 plus NO2
2 derived
from reduction of NO3
2.
Chemiluminescence was used for detection of NO2
2 after
its reduction to NO. We used a reducing medium consisting of
a ferrocene derivative dissolved in acetonitrile containing 1%
perchloric acid (Sigma). In this solution, NO is generated from
NO2
2 by a one-electron reduction pathway. In the reaction
vessel, helium is used as the carrier gas of NO to the NO
analyzer, at a rate of 35 ml/min. Reducing solutions (30 mg of
1,1-dimethylferrocene in 3 ml of acetonitrile, acidified with
50 ml of 70% perchloric acid) were freshly prepared and used
within 2 h (15). Under these conditions, NO2
2 in the injected
samples (50 ml) was reduced to NO and detected by chemilu-
minescence with a NO analyzer. Data were recorded automat-
ically on a chart recorder (Soltec Corporation) as previously
described (15).
NO2
2 and NO3
2 standard curves. Standard curves for
NO2
2 (0 to 80 mmol/L) and NO3
2 (0 to 80 mmol/liter) were
calculated by adding small aliquots (10 ml/50 ml sample) of
sodium nitrite or sodium nitrate solution (in degassed ultra-
pure water) (12). A standard curve relating the luminescence
produced by the added NO2
2 or NO3
2 was constructed, and
the data were fitted to a straight line (linear regression) (12).
All standard curves had r .0.96.
Calculation of NOx production equivalent. To estimate the
production of NOx by the heart, the arterial–venous difference
of NOx and coronary flow had to be known. NOx production by
the heart was calculated as: Output of NOx from the heart
(CSNOx 3 coronary flow) 2 Input of NOx into the heart
(ArterialNOx 3 coronary flow) (16). Because coronary flow was
not measured directly in these patients, data were used from
patients with AMI, in which coronary flow was calculated from
positron emission tomography imaging, using [13N]ammonia
(17). Czernin et al. (17) established a regression correlation
(r 5 0.74) relating the rate pressure product (RPP) to myo-
cardial blood flow as defined by the equation: y 5 0.00009x 2
0.07, where y 5 myocardial blood flow and x 5 RPP.
Using this equation we calculated mean coronary flow in
our patients. The production equivalent of NOx by the heart
could then be calculated. The term production equivalent was
used in preference to production because coronary flow was
not determined directly (12).
Statistical analysis. Two analyses were performed to eval-
uate the change in mean NOx levels over time. A two-way
analysis of variance with repeated-measures was used to ana-
lyze the difference in mean NOx levels over time in the venous,
arterial and coronary sinus plasma in patients with AMI. The
repeated measures model used a general covariance matrix,
allowing for unequal correlations over time. The design of this
study was an unbalanced two-way repeated measures analysis
of variance. All parameters (differences, means, p values) were
estimated via maximum likelihood. A second analysis was
performed comparing the mean NOx levels in the control
patients to the patients with AMI at 24, 48 and 72 h based on
between-group repeated measures variances for the peripheral
venous, arterial and coronary sinus blood.
To compare the three sources of mean NOx levels to each
other within each time period (control 24, 48 and 72 h),
post-hoc t tests (based on the covariance structure of the
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analysis of variance model) were performed using the Tukey-
Fisher least significant difference method. The within-subject
variances were used to calculate the standard errors.
A similar method was used to compare the mean NOx level
of the control group to the mean NOx levels at 24, 48 and 72 h.
Post-hoc t tests (based on the covariance structure of the
analysis of variance model) using the Tukey-Fisher least
significant difference method were used to compare these
means. The total variance estimated from the analysis of
variance model using a general covariance matrix was used to
calculate these standard errors. All variances used to calculate
the standard errors for the within-subject and between-subject
comparisons were estimated from the repeated measures of
the analysis of variance model using a general covariance
matrix, which allowed for unequal correlations over time. A p
value of 0.05 or less was considered statistically significant.
Data processing was performed using the SAS (version 6.11)
software package.
Results
Hemodynamic data (heart rate, mean blood pressure, left
ventricular end-diastolic pressure and left ventricular ejection
fraction in patients with and without myocardial infarction are
shown in Table 1. The infarction group had higher left
ventricular end-diastolic pressure and lower left ventricular
ejection fraction. The respective means for left ventricular
end-diastolic pressure in the two groups were 9.38 6
0.89 mm Hg in the control and 13.25 6 1.70 mm Hg in patients
with myocardial infarction (p , 0.05); left ventricular ejection
fraction was 66.13 6 2.49% in the control and 42.43 6 2.61%
in patients with infarction (p , 0.05). The possibility must be
considered that some of the changes in patients with myocar-
dial infarction were attributable to factors other than coronary
occlusion such as cigarette smoking or medication. Three of
the patients of the control group and five patients with
myocardial infarction were smokers. Smoking as a factor,
however, could be excluded. There were no statistical differ-
ence within each group for mean left ventricular end-diastolic
pressure or left ventricular ejection fraction or for coronary
sinus NOx concentration. There was also no difference in heart
rate or mean blood pressure. Diuretics and calcium antagonists
also did not influence NOx concentration in CS plasma. The
effect of other factors such as angiotension-converting enzyme
inhibitors or beta-adrenergic blocking agent could not be
evaluated because all but one patient were given angiotension-
converting enzyme inhibitors and only one patient was given
beta-blockers.
Table 2 shows that after onset of symptoms the values for
NOx in CS plasma are close to significance at 48 h (p , 0.07)
as compared to arterial and peripheral venous NOx concentra-
tions. At 24 h, CS NOx concentrations still exceed those in
arterial and peripheral venous plasma (Table 2). Compared to
the control group, all patients with AMI showed statistically
significant increase in NOx concentrations in arterial, CS and
peripheral venous plasma at 48 and 72 h after onset of
symptoms (Fig. 1). These statistical differences were absent
24 h after onset of symptoms. In Figure 2 the NOx levels in
arterial blood are plotted in each individual patient as a
function of time from the presentation through the remainder
of the study. The values of the control series are also shown. A
general increase in arterial NOx concentrations in individual
patients is noted. Changes in individual CS and peripheral
venous plasma followed a similar trend (not shown).
The coronary arterial–venous differences of NOx were
significantly greater when compared to their control and the
systemic arterial–venous NOx differences (Table 2). Forty-
eight hours after onset of symptoms the mean difference
between the coronary and systemic arterial–venous NOx dif-
ference was 6.0 mmol/L (p , 0.05). In control patients this
difference was not noted (Table 2). This suggests a cardiac
origin of NOx.
The output of NOx from the heart is represented as the
product of coronary flow and the NOx concentration in the CS
plasma (12,16). Because coronary flow was not determined
directly, it was calculated from the rate–pressure product as
presented in Table 3, according to methods of Czernin et al.
(17). From the coronary flow thus calculated the production
equivalent of NOx by the heart was obtained (12). The cardiac
NOx production equivalent is listed in Table 3. A multiple
comparison test showed that at 48 h after onset of symptoms
the NOx production equivalent was significantly greater than at
control, again pointing to the heart as the source of NOx
production (control 137 6 37 nmol/100 g/min; AMI at 48 h 5
472 6 104 nmol/100 g/min; p , 0.05; Table 3).
Discussion
Patients. Patients in this study represent a clinically ho-
mogenous population; none of them had cardiogenic shock or
congestive heart failure, and all had anterior myocardial
infarction with the left anterior descending coronary artery as
the culprit vessel. Furthermore all AMI patients had higher left
ventricular end-diastolic pressure and lower left ventricular
ejection fraction when compared to controls. Heart rate and
blood pressure did not differ (Table 1). Other factors such as
smoking, diuretics or calcium antagonists did not influence
either hemodynamics or NOx plasma concentration in patients
with AMI (Tables 1 and 2). The effect of angiotension-
converting enzyme inhibitors could not be evaluated, because
all but one patient was given angiotension-converting enzyme
inhibitors.
The angiotension-converting enzyme inhibitors may have
influenced NO production as inhibition of angiotension-
converting enzyme localized in the luminal site of the vascular
endothelium results in increased synthesis of NO and prosta-
glandin I2 by accumulation of endogenous bradykinin. This
demonstrates the potential ability to increase NO production
through the kinin pathway (18).
Formation of NOx. It is well known that NO is produced in
infarcted heart muscle primarily by the activity of iNOS (19).
Activation of iNOS occurs in cardiomyocytes and during the
376 AKIYAMA ET AL. JACC Vol. 32, No. 2
MYOCARDIAL INFARCTION AND NO OXIDATION August 1998:373–9
inflammatory phase in activated macrophages (11). iNOS
shows no requirement for Ca21 and calmodulin, although
calmodulin exists as a highly bound subunit (20). Activation of
iNOS depends on the release of endogenous substances,
including cytokines (tumor necrosis factor-alpha, interleukin-1
beta, interferon) (1). NO itself has an unpaired electron, and is
physiologically and pharmacologically active (21). In contrast,
as shown by Stuehr and Nathan (22), NO2
2 and NO3
2 are
inactive, except at acidic pH when NO2
2 is converted into
more reactive species. NO2
2 is formed by a reaction of NO
Figure 1. Mean plasma concentrations (mmol/L) of NOx from arterial
(closed circles), peripheral venous (open triangles) and coronary sinus
(open squares) plasma in control patients and in patients with AMI.
Plasma NOx concentrations are significantly elevated above control
values, at 48 and 72 h after onset of symptoms (p , 0.01). Values for
NOx in coronary sinus plasma significantly exceed those in peripheral
venous plasma from 24 to 72 h after onset of symptoms (p , 0.05). The
NOx values in coronary sinus plasma also significantly exceed those in
arterial plasma from 24 to 72 h after onset of symptoms (p , 0.05).
Figure 2. NOx concentrations in arterial plasma of individual AMI
patients increased from 24 to 48 h after onset of symptoms. The peak
NOx concentration usually occurred from 48 to 72 h after onset of
symptoms.
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with oxygen. The primary metabolite of NO is NO3
2 with
,10% of the total appearing as NO2
2 (23); NO2
2 concentra-
tions remain constant, whereas those of NO3
2 vary widely
(12,16). The sum of NO2
2 and NO3
2 has been designated as
NOx (12). The product of the reaction of NO with oxygen,
superoxide and transition metals support additional nitrosative
reactions (24). Hibbs et al. (8) showed that L-arginine is
required for activation of macrophages to a bactericidal and
tumoricidal state. Apparently NO is an intermediate in the
oxidation of L-arginine to NO2
2 and NO3
2 and the citrulline
pathway (25).
NOx and myocardial infarction. The results of the present
study provide evidence that in patients with anterior AMI at
48 h after onset of symptoms, NOx production equivalent by
the heart is increased together with its coronary arterial–
venous difference (Tables 2 and 3). This accounts for the
increase of NOx in arterial and peripheral venous plasma
(Table 2, Fig. 1). In experimental myocardial infarction acti-
vated macrophages are a major source of NO (26). An elevated
NOx production by the heart and increased concentrations of
NOx in peripheral venous blood have been noted previously in
rabbits 3 days after occlusion of a coronary artery (16). This
may have been the result of formation of NO by activated
macrophages (19). It is possible that both cardiomyocytes and
inflammatory cells, primarily activated macrophages, are in-
volved (11).
Although it is likely from the evidence presented here that
the elevated levels of NOx in peripheral plasma observed after
myocardial infarction are the result of increased production of
NOx by macrophages in infarcted heart muscle, the possibility
must be considered that other factors are involved. Part of
plasma NOx originates as a consequence of the activity of the
endothelial form of NO synthase. Evidence for this is the
finding of Akiyama et al. (12) that S-methylisothiourea, which
primarily inhibits iNOS, only partially lowers plasma levels of
NOx. It is unlikely that coronary angioplasty influences the
results as collections of plasma for NOx determination were
carried out $18 h after angioplasty. Another possible reason
for the increase of NOx in plasma is accumulation of nitrate
anion if the production of NOx exceeds its elimination within
the half-life of NOx (3.8 h) (16). Similarly, diminished clear-
ance of NOx by the kidney can lead to increased NOx plasma
levels. This may be the case in severe congestive heart failure
as reported by Winlaw et al. (27). However, none of the
patients in this series had signs of congestive heart failure.
Another possible explanation for increased appearance of
NOx in CS plasma is enhanced NO production originating in
coronary vascular endothelium beginning 24 h after reperfu-
sion. Kim et al. (28) have shown that brief ischemic episodes
are responsible for enhanced coronary artery endothelial func-
tion. This effect is delayed in onset and prolonged in duration.
This may be one of the factors responsible for the increased
concentration of NOx in CS plasma of patients after onset of
acute myocardial infarction. It also suggests that in certain
instances involving multiple factors NOx in plasma may not be
the exclusive reflection of iNOS in heart muscle.
Table 3. Calculation of Cardiac NOx Production Equivalent
Control Group AMI Group
No. No 24 H 48 H 72 H
1
HR 67 1 88 86 72
BP 130 112 115 120
RPP 8710 9856 9890 8640
CS flow 71.39 81.7 82.01 70.76
NOx Eq 48.55 333.34 435.47 173.36
2
HR 70 2 72 68 86
BP 120 128 119 120
RPP 8400 9216 8092 10320
CS flow 68.6 75.95 65.83 85.88
NOx Eq 74.77 151.14 436.45 227.58
3
HR 59 3 96 88 —
BP 140 101 110 —
RPP 8260 9696 9680 —
CS flow 67.34 80.26 80.12 —
NOx Eq 91.58 574.66 741.11 —
4
HR 79 4 68 74 —
BP 144 120 134 —
RPP 11376 8160 9916 —
CS flow 95.38 66.44 82.24 —
NOx Eq 103.01 495.64 270.57 —
5
HR 90 5 82 74 82
BP 124 105 103 100
RPP 11160 8610 7622 8200
CS flow 93.44 70.49 61.6 66.8
NOx Eq 350.4 47.93 356.66 249.83
6
HR 74 6 84 80 90
BP 100 110 116 108
RPP 7400 9240 9280 9720
CS flow 59.6 76.16 76.52 80.48
NOx Eq 40.53 207.16 — 511.85
7
HR 70 7 80 84 82
BP 150 118 112 116
RPP 10500 9440 9408 9512
CS flow 87.5 77.96 77.67 78.61
NOx Eq 238 247.91 930.49 202.03
8
HR 75 8 70 74 72
BP 130 134 121 122
RPP 9750 9380 8954 8784
CS flow 80.75 77.42 73.58 72.06
NOx Eq 192.19 6.19 135.39 53.32
Mean HR 73.0 6 3.2 80.0 6 3.4 78.5 6 2.5 80.7 6 3.0
Mean BP 130 6 6 116 6 4 117 6 3 114 6 4
Mean RPP 9444 6 519 9200 6 198 9105 6 298 9196 6 322
Mean CS flow 77.9 6 4.6 75.6 6 1.9 74.9 6 2.7 75.8 6 2.9
Mean NOx Eq 137 6 37 240 6 77 472 6 104* 236 6 62
*p , 0.05 versus control. HR 5 heart rate (beats/min); BP 5 blood pressure
(mm Hg); RPP 5 rate pressure product; CS flow 5 coronary sinus flow (ml/100
g/min); NOx Eq 5 cardiac NOx production equivalent (nmol/100 g/min).
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Our observations of increased arteriocoronary sinus differ-
ence and of NOx myocardial production equivalent strongly
point to the heart as a source of increased plasma levels of NOx
in myocardial infarction.
Nitric oxide and cardiac disorders. Cardiac diseases other
than myocardial infarction are accompanied by changes in
plasma concentration of NO3
2 (29,30). Winlaw et al. (27)
reported that plasma NO3
2 increased significantly in patients
with chronic congestive heart failure; however, because only
peripheral plasma concentrations were measured, decrease in
renal function may have been partially responsible. Haywood
et al. (31) found increased expression of inducible form of
nitric oxide synthase messenger RNA in the hearts of patients
with chronic congestive heart failure. Langrehr et al. (29)
demonstrated in allografted rats a significant increase in
NO2
2/NO3
2 levels in peripheral blood before critical signs of
rejection were noted. Treatment with FK-506, an inhibitor of
transplant rejection, abolished this increase. Winlaw et al. (32)
found in rats an eightfold increased excretion of urinary
NO2
2 in untreated allograft rejection. Akiyama et al. (12)
also reported reduction of plasma levels of NOx by
S-methylisothiourea, a selective inhibitor of iNOS in experi-
mental myocardial infarction in rabbits.
Conclusions. From data presented in this report, no defi-
nite conclusions on future applications of NOx determinations
in peripheral blood of patients with myocardial infarction can
be drawn. More patients need to be studied and the various
parameters responsible for increased NOx production should
be further defined. However, the evidence of a cardiac origin in
the increase in plasma NOx concentration in patients with
myocardial infarction appears convincing.
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